1. Medical History and Approved Indications.

Oxymetholone received its FDA approval for clinical use back in 1961. Unlike many other anabolic steroids from that time. Researchers developed it to enhance red blood cell production and aid patients with severe wasting diseases.

Its approved clinical indications include:
• Severe Anemias: Specifically aplastic anemia, myelofibrosis, and refractory anemias, due to its ability to stimulate the production of erythropoietin (the hormone responsible for red blood cell generation).
• Muscle Wasting Disorders: Used historically to preserve lean muscle tissue in patients suffering from cachexia, advanced HIV/AIDS, or severe burns.
• Osteoporosis: Used occasionally in the past to aid in bone density restoration, though newer non-steroidal treatments have largely replaced it for this indication.

With the advent of recombinant human erythropoietin (Epogen) and advanced non-steroidal treatments. The clinical use of oxymetholone has significantly diminished. Though it remains an approved prescription medication for specific refractory cases.

2. Pharmacology and Mechanism of Action.

Oxymetholone is a modified version of dihydrotestosterone. To ensure the hormone can be taken orally, researchers introduced a methyl group at the 17th carbon position (C17-alpha alkylation). Without this adjustment, the liver would quickly break down the compound before it had a chance to enter the bloodstream.

• Androgenic vs. Anabolic Rating. Oxymetholone has a high anabolic rating of 320, much greater than testosterone’s 100, but with low androgen receptor binding. It exerts its effects largely through non-receptor-mediated mechanisms, making its tissue-building properties exceptionally rapid.
• Lack of Aromatization. Because it is a DHT derivative, oxymetholone cannot be converted into estrogen via the aromatase enzyme. However, it is unique because it still exhibits significant estrogenic activity. Research suggests it may directly stimulate estrogen receptors or interact with progesterone receptors.

Adverse Effects and Clinical Risks

Hepatotoxicity (Liver Stress).
As an oral C17-alpha alkylated steroid, oxymetholone resists hepatic breakdown, placing significant strain on the liver.
• Clinical Risks: Prolonged exposure or high doses can lead to peliosis hepatis (blood-filled cysts in the liver), cholestatic hepatitis, elevated liver enzymes (AST/ALT), and in rare cases, hepatic tumors.

Cardiovascular Strain.
Oxymetholone negatively impacts the cardiovascular system through multiple pathways:
• Lipid Profiles: It drastically suppresses high-density lipoprotein (HDL/”good” cholesterol) and increases low-density lipoprotein (LDL/”bad” cholesterol).
• Water Retention and Hypertension: Due to its estrogenic activity, users often experience severe fluid retention, which directly increases blood pressure (hypertension) and strain on the left ventricle of the heart.
• Polycythemia: Because it stimulates red blood cell production, it can excessivel > UnlimAI (GPT | Claude | MidJourney): y increase blood viscosity (hematocrit), raising the risk of blood clots, strokes, and cardiovascular events.

Endocrine and Hormonal Disruption
• HPTA Suppression: Oxymetholone causes severe, rapid suppression of the Hypothalamic-Pituitary-Testicular Axis (HPTA). This leads to a complete shutdown of natural testosterone production, testicular atrophy, and temporary or permanent infertility.
• Estrogenic Side Effects. Despite not aromatizing, it can cause severe gynecomastia (breast tissue development in males) and significant subcutaneous water retention.
• Androgenic Side Effects. Highly sensitive individuals may experience accelerated male pattern baldness (androgenic alopecia), severe acne, and virilization (development of male characteristics) in female patients.